DG
ADMA icon

Delek Group’s ADMA Biologics ADMA Stock Holding History

Delek Group’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		$129K Sell
34,034
-30,000
-47% -$132K 0.01% 218
2019
Q1 		$241K Sell
64,034
-54,505
-46% -$193K 0.01% 194
2018
Q4 		$291K Buy
118,539
+60,000
+102% +$297K 0.01% 205
2018
Q3 		$361K Buy
+58,539
New +$337K 0.02% 215

Other funds holding ADMA

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Delek Group's ADMA Position: Q2 2019 in Review

Delek Group reduced its ADMA Biologics (ADMA) stake by 47% in Q2 2019, selling an estimated $132K and leaving 34,034 shares worth $129K. The position accounts for 0.01% of the portfolio, ranked #218.

Delek Group first reported a position in ADMA in Q3 2018 and has held it in 4 quarters since. The position peaked at $361K in Q3 2018. 67 funds tracked by Wall St. Rank hold ADMA as of Q2 2019.

  • Delek Group held 34,034 shares of ADMA Biologics worth $129K as of Q2 2019.
  • Delek Group sold 30,000 ADMA Biologics shares in Q2 2019, an estimated $132K.
  • ADMA Biologics made up 0.01% of Delek Group's portfolio in Q2 2019, its #218 holding.
  • Delek Group first reported a position in ADMA Biologics in Q3 2018 and has held it in 4 quarters since.
  • Delek Group's ADMA Biologics position peaked at $361K in Q3 2018.
  • 67 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2019.

Based on Delek Group's 13F filing for Q2 2019, filed 8 Aug 2019.